Simulations Plus - SLP Stock Forecast, Price & News

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on SLP. Craig Hallum increased their price target on shares of Simulations Plus from $55.00 to $60.00 and gave the stock a "buy" rating in a research note on Thursday, July 7th. TheStreet raised shares of Simulations Plus from a "c+" rating to a "b-" rating in a research report on Friday, July 22nd.

Simulations Plus Stock Performance

NASDAQ:SLP traded up $0.57 on Monday, reaching $64.76. The company's stock had a trading volume of 1,271 shares, compared to its average volume of 123,034. The firm's 50 day moving average is $54.70 and its two-hundred day moving average is $48.13. The stock has a market cap of $1.31 billion, a PE ratio of 112.62 and a beta of 0.42. Simulations Plus has a twelve month low of $35.18 and a twelve month high of $67.59.

Simulations Plus (NASDAQ:SLP - Get Rating) last released its quarterly earnings data on Wednesday, July 6th. The technology company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.17 by $0.03. Simulations Plus had a return on equity of 6.91% and a net margin of 22.74%. The firm had revenue of $14.96 million for the quarter, compared to the consensus estimate of $14.33 million. During the same quarter in the prior year, the company posted $0.18 earnings per share. The firm's revenue was up 17.1% on a year-over-year basis. Equities research analysts anticipate that Simulations Plus will post 0.64 EPS for the current fiscal year.

Simulations Plus Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 1st. Stockholders of record on Monday, July 25th were paid a $0.06 dividend. The ex-dividend date of this dividend was Friday, July 22nd. This represents a $0.24 dividend on an annualized basis and a dividend yield of 0.37%. Simulations Plus's dividend payout ratio (DPR) is presently 42.11%.

Insider Buying and Selling

In other Simulations Plus news, Director Walter S. Woltosz sold 17,461 shares of the firm's stock in a transaction dated Tuesday, June 28th. The stock was sold at an average price of $48.00, for a total transaction of $838,128.00. Following the transaction, the director now owns 4,140,173 shares in the company, valued at $198,728,304. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, Director Walter S. Woltosz sold 20,000 shares of the business's stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $61.19, for a total transaction of $1,223,800.00. Following the completion of the transaction, the director now owns 4,117,634 shares of the company's stock, valued at approximately $251,958,024.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Walter S. Woltosz sold 17,461 shares of the company's stock in a transaction dated Tuesday, June 28th. The stock was sold at an average price of $48.00, for a total value of $838,128.00. Following the completion of the transaction, the director now directly owns 4,140,173 shares of the company's stock, valued at approximately $198,728,304. The disclosure for this sale can be found here. Insiders sold a total of 57,461 shares of company stock worth $3,021,728 over the last three months. 23.08% of the stock is currently owned by company insiders.